Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 3;388(10061):2796-2810.
doi: 10.1016/S0140-6736(16)30512-8. Epub 2016 Jun 23.

Bladder cancer

Ashish M Kamat  1 , Noah M Hahn  2 , Jason A Efstathiou  3 , Seth P Lerner  4 , Per-Uno Malmström  5 , Woonyoung Choi  6 , Charles C Guo  7 , Yair Lotan  8 , Wassim Kassouf  9
Affiliations
Review

Bladder cancer

Ashish M Kamat et al. Lancet. .

Erratum in

  • Department of Error.
    [No authors listed] [No authors listed] Lancet. 2016 Dec 3;388(10061):2742. doi: 10.1016/S0140-6736(16)31776-7. Epub 2016 Sep 29. Lancet. 2016. PMID: 27692746 No abstract available.

Abstract

Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.

Trial registration: ClinicalTrials.gov NCT01224665.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Associated data